Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.

Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents

NCT00907062

Vitiligo Vulgaris

COMPLETED PHASE1

Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo

NCT03487042

Generalized Vitiligo

UNKNOWN PHASE4

Efficacy and Safety of Total Glucosides of Paeony Combined With NB-UVB on Treating Vitiligo

NCT03608917

Vitiligo

COMPLETED NA

Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo

NCT02506101

Vitiligo Pigmentation Dyschromia

TERMINATED NA

Phototherapy Combination With Topicals in Vitiligo

NCT04440371

Vitiligo, Generalized

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB) might give better results than using either one alone. This might improve repigmentation as well as patients' quality-of-life. (QOL).

This will be a prospective double-blind randomized controlled clinical trial. One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per group).

One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly.

The other group will receive placebo tablets( identical in size, shape and color) to GB twice daily with NBUVB twice weekly.

Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for both groups.

Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than placebo or not.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GINGKO BILOBA

MEMOREX 60 MG BID

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo.
* Body surface area (BSA) involvement ≥ 3%.

Exclusion Criteria

* Unable to consent
* Any topical, systemic or phototherapy for Vitiligo in the previous 2 months.
* Pregnancy, breast feeding.
* Liver or kidney disease.
* Epilepsy
* Bleeding disorder or anticoagulant treatment

Minimum Eligible Age

12 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No